ClinicalTrials.gg
Active, not recruitingNCT06041529Updated Feb 13, 2026

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

A Phase 4 interventional study of Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg and Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg in Essential Hypertension, sponsored by Yuhan Corporation. Active, not recruiting at 15 sites in South Korea. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.

Started
2023
with 1 other
Phase 4
Only one
of the 10
Registered
3rd of 10
by date

Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is one of 2 that started in 2023, is the only one in phase 4, and was the 3rd registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Essential Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations

Read the detailed description

This is a Phase IV, Randomized, Open-label, Superiority, Comparative study evaluating the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination) versus Telmisartan, Amlodipine, and Hydrochlorothiazide in eledrly patient with essential hypertension uncontrolled by Telmisartan and Amlodipine Combinations.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Telmisartan/Amlodipine/Chlorthalidone Fixed-Dose Combination
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who have been fully informed about the purpose, content, and characteristics of product, and have voluntarily agreed in writing
  2. Aged ≥ 65 with essential hypertension
  3. Patient with uncontrolled essential hypertension at screening

    • If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP \< 200 mmHg
    • If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP \< 200 mmHg

Exclusion criteria

Exclusion Criteria:

  1. Patient who has history of drug allergic reactions
  2. Known to components of the product
  3. Patient who is unable to stop taking prohibited drugs
  4. Test results showing the following values at screening

    • The change of MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg on target arm between 1st and 2nd measurements
  5. Pregnant or lactating women
  6. Patient who is unable to maintain proper night sleep
  7. Malnutrition, starvation, debilitating factors, A person who is being forcibly detained for the treatment of mental or physical
  8. Administration of other investigational products within 3 months prior to screening.
  9. An impossible one who participates in clinical trial by investigator's decision
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg

    Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg will be orally administered during the study period

    Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg

  • Active comparator
    Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

    Telmisartan/Amlodipine 40/5 mg and Hydrochlorothiazide 25 mg will be orally administered each during study period

    Drug: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

Interventions

  • DrugTelmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg

    PO, Once daily(QD), 8 weeks and 26 weeks if applicable

    Also known as: Truset 40/5/12.5mg

  • DrugTelmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

    PO, Once daily(QD), 8 weeks and 26 weeks if applicable

    Also known as: Twynsta 40/5 mg, Dichlozid 25 mg

06

What researchers measure

Primary outcomes

  1. Mean Systolic Blood Pressure (MSBP) in nighttime

    To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 8

    Time frame: Week 8

Secondary outcomes

  1. Mean Systolic Blood Pressure (MSBP) in nighttime

    To evaluate change from baseline in nighttime Mean Systolic Blood Pressure (MSBP) measured by Ambulatory Blood Pressure Monitoring at Week 26 if applicable

    Time frame: Week 26 if applicable

  2. Mean Diastolic Blood Pressure (MDBP) in nighttime

    To evaluate change from baseline in nighttime Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable

    Time frame: Week 8 and Week 26 if applicable

  3. Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) in daytime

    To evaluate change from baseline in daytime Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable

    Time frame: Week 8 and Week 26 if applicable

  4. 24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP)

    To evaluate change from baseline in 24-hour Mean Systolic Blood Pressure (MSBP)/Mean Diastolic Blood Pressure (MDBP) measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable

    Time frame: Week 8 and Week 26 if applicable

  5. Patients Achieving in nighttime Mean Systolic Blood Pressure (MSBP)

    To evaluate the percentage of patients who reached the treatment goal for nighttime Mean Systolic Blood Pressure (MSBP) (\<110/65mmHg) measured by Ambulatory Blood Pressure Monitoring at Week 8

    Time frame: Week 8

  6. Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP)

    To evaluate change from baseline in Mean Sitting Systolic Blood Pressure (MSSBP)/ Mean Sitting Diastolic Blood Pressure (MSDBP) measured by the Institution at Week 4, Week 8 and Week 26 if applicable

    Time frame: Week 4, Week 8 and Week 26 if applicable

  7. Patients Achieving in Mean Sitting Systolic Blood Pressure (MSSBP)

    \- To evaluate the percentage of patients who reached the treatment goal for Mean Sitting Blood Pressure (MSBP) \< 140/90 mmHg measured by the Institution at Week 4, Week 8 and Week 26 if applicable

    Time frame: Week 4, Week 8 and Week 26 if applicable

  8. Percentage of patients with decreased Mean Sitting Systolic Blood Pressure (MSSBP) and Mean Sitting Diastolic Blood Pressure (MSDBP).

    To evaluate the percentage of subjects with a Mean Sitting Systolic Blood Pressure (MSSBP) decrease of ≥20mmHg and a Mean Sitting Diastolic Blood Pressure (MSDBP) decrease of ≥10mmHg at Week 4, Week 8 and Week 26 if applicable

    Time frame: Week 4, Week 8 and Week 26 if applicable

  9. T/P ratio

    To evaluate the T/P ratio for systolic/diastolic blood pressure measured by Ambulatory Blood Pressure Monitoring at Week 8 and Week 26 if applicable

    Time frame: Week 8 and Week 26 if applicable

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Feb 2026, 28 months after the start.

Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Sep 18, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06041529
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Oct 18, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Sanghyun Ihm
principal investigator · The Catholic University of Korea Bucheon St.Mary's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion